[Efficacy and safety of fourth-generation CAR-T cells targeting CD19 and BCMA with anti-IL-6 antibody secretion in refractory systemic lupus erythematosus].

医学 细胞因子释放综合征 不利影响 免疫学 抗体 环磷酰胺 内科学 耐火材料(行星科学) CD19 痹症科 抗原 自身免疫性疾病 CD8型 免疫系统 系统性红斑狼疮 外周水肿 B细胞激活因子 红斑狼疮 细胞因子 胃肠病学 免疫疗法 甲氨蝶呤 全身性疾病
作者
X X Xu,Q Wang,X J Zhao,N Xiang,B L Hu,X B Wang,Z Chen
出处
期刊:PubMed [National Institutes of Health]
卷期号:106 (23): 2378-2383
标识
DOI:10.3760/cma.j.cn112137-20251226-03435
摘要

Clinical data of 3 patients with refractory systemic lupus erythematosus (rSLE) who received chimeric antigen receptor T-cell (CAR-T) therapy at the Department of Rheumatology and Immunology, the First Affiliated Hospital of University of Science and Technology of China, from June to September 2024 was prospectively enrolled. After lymphodepleting preconditioning with cyclophosphamide combined with fludarabine, 2 patients received a low dose (0.5×10⁶/kg) and 1 patient received a medium dose (1.0×10⁶/kg) of a 4th-generation CAR-T cells (SCAR02) targeting cluster of differentiation 19 (CD19) and B-cell maturation antigen (BCMA) and secreting interleukin-6 (IL-6) antibodies. Follow-up was conducted at day 14 and months 1, 2, 3, 6, 9, and 12 post-infusion to systematically evaluate safety (including treatment-related adverse events, cytokines, and immunoglobulin levels) and efficacy (including cellular kinetics, clinical efficacy, and serological markers). All 3 patients were females, aged 37, 25, and 41 years, respectively. During the follow-up period, no cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or other serious adverse events occurred. CAR-T cells expanded well in all patients; peripheral blood CD19⁺ B cells were completely depleted on days 9-13 and gradually recovered over 3-5 months. By month 12, the SLE Disease Activity Index 2000 (SLEDAI-2K) scores of patients 1 to 3 decreased from 8, 8, and 9 at baseline to 0, 4, and 0, respectively; anti-double-stranded DNA antibodies all turned negative, and complement levels returned to normal. Two patients achieved drug-free complete remission based on the Definitions of Remission in SLE (DORIS) criteria, and 1 patient achieved an SLE Responder Index-4 (SRI-4) response. This study demonstrates that SCAR02 exhibits a good safety profile and preliminary efficacy in rSLE patients, and its function of secreting IL-6 antibodies may help alleviate CRS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Sylvia发布了新的文献求助10
刚刚
luobeimin发布了新的文献求助10
刚刚
天生骄傲发布了新的文献求助10
刚刚
许木完成签到,获得积分10
刚刚
1秒前
1秒前
今后的应助被xxxxfiona采纳,获得10
1秒前
antares完成签到,获得积分10
1秒前
1秒前
世一上宙活完成签到,获得积分10
1秒前
1秒前
1秒前
gavincsu完成签到,获得积分10
2秒前
qazplm发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
3秒前
3秒前
3秒前
向日葵完成签到,获得积分10
3秒前
我是老大的应助被keyangouderic采纳,获得10
3秒前
琅冰冰完成签到,获得积分10
4秒前
科研通AI6.2的应助被baboon222采纳,获得10
4秒前
4秒前
5秒前
加速度发布了新的文献求助10
5秒前
顺心的尔白完成签到,获得积分10
5秒前
5秒前
甜甜玫瑰完成签到,获得积分0
5秒前
彭于晏的应助被实验室采纳,获得10
6秒前
null的应助被gavincsu采纳,获得10
6秒前
6秒前
7秒前
wbw完成签到 ,获得积分10
8秒前
8秒前
lmei完成签到 ,获得积分10
8秒前
风格的应助被糊涂的缘分采纳,获得30
8秒前
8秒前
NexusExplorer的应助被123采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153492
求助须知:如何正确求助?哪些是违规求助? 9550166
关于积分的说明 21696892
捐赠科研通 7742051
什么是DOI,文献DOI怎么找? 3425502
关于科研通互助平台的介绍 2550620
邀请新用户注册赠送积分活动 2469156